Indwelling catheters and medical implants with FXIIIa inhibitors: A novel approach to the treatment of catheter and medical device-related infections

• Published in: European journal of pharmaceutics and biopharmaceutics 2013-01, Vol.83 (1), p.106-113
• Main Authors: Daneshpour, Nooshin, Collighan, Russell, Perrie, Yvonne, Lambert, Peter, Rathbone, Dan, Lowry, Deborah, Griffin, Martin
• Format: Article
• Language: English
• Subjects: Catheter-related complications; Catheter-related infection; Catheter-Related Infections - prevention & control; Catheter-related thrombosis; Catheters, Indwelling - adverse effects; Central venous catheter; Central Venous Catheters - adverse effects; Dipeptides - administration & dosage; Dipeptides - pharmacology; Drug Delivery Systems; Equipment and Supplies - adverse effects; Factor XIIIa - antagonists & inhibitors; FXIIIa inhibitor; Humans; Silicone Elastomers - chemistry; Sulfonamides - administration & dosage; Sulfonamides - pharmacology; Transglutaminase
• ISSN: 0939-6411; 1873-3441
• DOI: 10.1016/j.ejpb.2012.09.005

A Factor XIIIa inhibitor-containing silicon central venous catheter inhibits thrombus formation and entrapment/cross-linking of Staphylococcus aureus to prevent thrombotic occlusion and catheter-related blood stream infections. Central venous catheters (CVCs) are being utilized with increasing frequency in intensive care and general medical wards. In spite of the extensive experience gained in their application, CVCs are related to the long-term risks of catheter sheath formation, infection, and thrombosis (of the catheter or vessel itself) during catheterization. Such CVC-related-complications are associated with increased morbidity, mortality, duration of hospitalization, and medical care cost [1]. The present study incorporates a novel group of Factor XIIIa (FXIIIa, plasma transglutaminase) inhibitors into a lubricious silicone elastomer in order to generate an optimized drug delivery system whereby a secondary sustained drug release profile occurs following an initial burst release for catheters and other medical devices. We propose that the incorporation of FXIIIa inhibitors into catheters, stents, and other medical implant devices would reduce the incidence of catheter sheath formation, thrombotic occlusion, and associated staphylococcal infection. This technique could be used as a local delivery system for extended release with an immediate onset of action for other poorly aqueous soluble compounds.